BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2023 2:28:02 PM | Browse: 578 | Download: 1538
Publication Name World Journal of Clinical Cases
Manuscript ID 87241
Country China
Received
2023-08-21 09:34
Peer-Review Started
2023-08-21 09:34
First Decision by Editorial Office Director
2023-09-04 02:57
Return for Revision
2023-09-04 02:57
Revised
2023-09-12 06:57
Publication Fee Transferred
Editorial Processing by Scientific Editor
2023-09-21 02:52
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2023-09-22 07:28
Articles in Press
2023-09-22 07:28
Edit the Manuscript by Language Editor
Typeset the Manuscript
2023-09-27 06:49
Publish the Manuscript Online
2023-10-13 14:28
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Hematology
Manuscript Type Meta-Analysis
Article Title Meta analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
Manuscript Source Unsolicited Manuscript
All Author List Pei Wang and Sheng-Yu Jin
ORCID
Author(s) ORCID Number
Pei Wang http://orcid.org/0009-0002-2077-0830
Sheng-Yu Jin http://orcid.org/0000-0002-9973-0737
Funding Agency and Grant Number
Corresponding Author Sheng-Yu Jin, PhD, Chief Doctor, Doctor, Doctor, Library Staff, Department of Hematology, Yanbian University Hospital, 1327 Juzi Street, Yanji 133000, Jilin Province, China. jinsy11@163.com
Key Words Multiple myeloma; Daratumumab; Efficacy; Safety; Meta-analysis
Core Tip Daratumumab demonstrates promising efficacy in treating multiple myeloma, improving the ORR, CR, and PFS, compared to other therapies. However, it is also associated with an increased risk of neutropenia and thrombocytopenia. Clinicians should closely monitor their patients for these adverse effects. Further studies are needed to explore optimal dosing and combination therapies to maximize the benefits of dDaratumumab in treating multiple myeloma.
Publish Date 2023-10-13 14:28
Citation Wang P, Jin SY. Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma. World J Clin Cases 2023; 11(29): 7091-7100
URL https://www.wjgnet.com/2307-8960/full/v11/i29/7091htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i29.7091
Full Article (PDF) WJCC-11-7091-with-cover.pdf
Full Article (Word) WJCC-11-7091.docx